Quest Diagnostics Inc. (NYSE:DGX) reports preliminary financial results for the quarter ended 2012-09-30.
Quest Diagnostics Inc. recently reported its preliminary financial results, based on which CapitalCube provides a unique peer-based analysis of the company. Our analysis is based on the company's performance over the last 12 months (unless stated otherwise).
Quest Diagnostics Inc.'s analysis versus peers uses the following peer-set: Laboratory Corp. of America Holdings (NYSE:LH), Sonic Healthcare Ltd. (OTCPK:SKHCF), Qiagen N.V. (NASDAQ:QGEN), Alere Inc. (NYSE:ALR), Genomic Health Inc. (NASDAQ:GHDX) and Bio-Reference Laboratories Inc. (NASDAQ:BRLI). The table below shows the preliminary results, along with the recent trend for revenues, net income and returns.
|Quarterly (USD million)||2012-09-30||2012-06-30||2012-03-31||2011-12-31||2011-09-30|
|Revenue Growth %||(2.9)||(1.5)||3.0||(1.4)||0.2|
|Net Income Growth %||(8.2)||11.9||(16.3)||10.3||5.2|
|Net Margin %||8.8||9.3||8.2||10.1||9.0|
|ROE % (Annualized)||16.0||18.1||16.8||21.1||19.8|
|ROA % (Annualized)||7.0||7.5||6.8||8.1||7.3|
Quest Diagnostics Inc.'s current Price/Book of 2.4 is about median in its peer group. We classify Quest Diagnostics Inc. as Harvesting because of the market's low expectations for growth (PE of 14.8 compared to peer median of 19.8), despite its relatively high returns (ROE of 17.9% compared to the peer median ROE of 12.4%).
The company's asset efficiency (asset turns of 0.8x) and net profit margins of 9.1% are both median for its peer group. Quest Diagnostics Inc.'s net margin has increased 2.9 percentage points from last year's low, and is now above its five-year average net margin of 8.6.
Changes in the company's annual top line and earnings (1.9% and -35.1% respectively) generally lag its peers. This implies a lack of strategic focus and/or inability to execute. We view such companies as laggards relative to peers.
Quest Diagnostics Inc.'s current return on assets is around peer median (7.4% vs. peer median 6.6%). This contrasts with its higher than peer median return on assets over the past five years (7.5% vs. peer median 6.1%), suggesting that the company's relative operating performance has declined.
The company's gross margin of 44.9% is around peer median, suggesting that Quest Diagnostics Inc.'s operations do not benefit from any differentiating pricing advantage. However, Quest Diagnostics Inc.'s pre-tax margin is more than the peer median (14.9% compared to 11.1%), suggesting relatively tight control on operating costs.
Growth And Investment Strategy
Quest Diagnostics Inc.'s revenues have grown more slowly than the peer median over the last few years (1.2% vs. 9.4%, respectively for the past three years), and the stock price's relatively low PE ratio of 14.8 implies relatively low future growth as well. Overall, we view the company's growth expectations as substandard relative to its peers.
Quest Diagnostics Inc.'s annualized rate of change in capital of 4.9% over the past three years is less than its peer median of 8.9%. This investment has generated a better than peer median return on capital of 9.1% averaged over the same three years. This combination of a relatively low investment with good returns suggests that the company is likely milking its business.
Quest Diagnostics Inc.'s net income margin for the last 12 months is around the peer median (9.1% vs. peer median of 7.9%). This average margin, combined with a level of accruals that is around peer median (6.0% vs. peer median of 6.0%), suggests there possibly isn't too much accrual movement flowing into the company's reported earnings.
Quest Diagnostics Inc.'s accruals over the last 12 months are positive, suggesting a buildup of reserves. However, this level of accruals is also around the peer median, and suggests the company is recording a proper level of reserves compared to its peers.
Quest Diagnostics, Inc. is engaged in providing diagnostic testing, information and services that help patients, physicians and others to make better healthcare decisions. It offers patients and physicians the broadest access to diagnostic laboratory services through the company's nationwide network of laboratories and patient service centers. The company was spun off from the Corning, Inc. as an independent company on December 31, 1996. Quest Diagnostics was founded in 1967 by Dr. Paul Brown and is headquartered in Madison, NJ.
Disclaimer: The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party's use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you're agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website analytixinsight.com.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.